209 related articles for article (PubMed ID: 32730628)
41. Time-dependent benefits of pre-treatment with new oral P2Y
Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S
Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413
[TBL] [Abstract][Full Text] [Related]
42. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.
Ubaid S; Ford TJ; Berry C; Murray HM; Wrigley B; Khan N; Thomas MR; Armesilla AL; Townend JN; Khogali SS; Munir S; Martins J; Hothi SS; McAlindon EJ; Cotton JM
Thromb Haemost; 2019 Jul; 119(7):1171-1181. PubMed ID: 31129911
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions.
Schmucker J; Fach A; Mata Marin LA; Retzlaff T; Osteresch R; Kollhorst B; Hambrecht R; Pohlabeln H; Wienbergen H
J Am Heart Assoc; 2019 Sep; 8(18):e012530. PubMed ID: 31538856
[TBL] [Abstract][Full Text] [Related]
44. Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facility.
Lupi A; Schaffer A; Lazzero M; Tessitori M; De Martino L; Rognoni A; Bongo AS; Porto I
Cardiovasc Revasc Med; 2016 Dec; 17(8):528-534. PubMed ID: 27666002
[TBL] [Abstract][Full Text] [Related]
45. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
Dehghani P; Lavoie A; Lavi S; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN
Am Heart J; 2017 Oct; 192():105-112. PubMed ID: 28938956
[TBL] [Abstract][Full Text] [Related]
46. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
[TBL] [Abstract][Full Text] [Related]
47. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study.
Janssens GN; van Leeuwen MAH; van der Hoeven NW; de Waard GA; Nijveldt R; Diletti R; Zijlstra F; von Birgelen C; Escaned J; Valgimigli M; van Royen N
J Cardiovasc Transl Res; 2016 Jun; 9(3):249-256. PubMed ID: 27102290
[TBL] [Abstract][Full Text] [Related]
48. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
49. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
[TBL] [Abstract][Full Text] [Related]
50. Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Gach O; Nyssen A; Pirlet C; Magne J; Oury C; Lancellotti P
J Cardiovasc Med (Hagerstown); 2018 May; 19(5):234-239. PubMed ID: 29528868
[TBL] [Abstract][Full Text] [Related]
51. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study.
Kubica J; Adamski P; Buszko K; Barańska M; Sikora J; Marszałł MP; Sobczak P; Sikora A; Kuliczkowski W; Fabiszak T; Kubica A; Jilma B; Alexopoulos D; Navarese EP
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):139-148. PubMed ID: 30689800
[TBL] [Abstract][Full Text] [Related]
52. Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration.
Wang Y; Wu H; Chen Y; Wang Q; Qian J; Ge J
Adv Ther; 2020 Oct; 37(10):4220-4232. PubMed ID: 32770531
[TBL] [Abstract][Full Text] [Related]
53. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?
Alexopoulos D; Moulias A; Kanakakis I; Xanthopoulou I
Int J Cardiol; 2015 Sep; 194():41-3. PubMed ID: 26011263
[TBL] [Abstract][Full Text] [Related]
54. Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.
Abo-Aly M; George B; Shokri E; Chelvarajan L; El-Helw M; Smyth SS; Abdel-Latif A; Ziada K
J Thromb Thrombolysis; 2021 Oct; 52(3):934-940. PubMed ID: 33258102
[TBL] [Abstract][Full Text] [Related]
55. Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).
Park SD; Lee MJ; Baek YS; Kwon SW; Shin SH; Woo SI; Kim DH; Kwan J; Park KS
EuroIntervention; 2016 Oct; 12(8):e964-e971. PubMed ID: 27721212
[TBL] [Abstract][Full Text] [Related]
56. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
[TBL] [Abstract][Full Text] [Related]
57. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
[TBL] [Abstract][Full Text] [Related]
58. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
[TBL] [Abstract][Full Text] [Related]
59. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
Redfors B; Dworeck C; Haraldsson I; Angerås O; Odenstedt J; Ioanes D; Petursson P; Völz S; Albertsson P; Råmunddal T; Persson J; Koul S; Erlinge D; Omerovic E
Eur Heart J; 2019 Apr; 40(15):1202-1210. PubMed ID: 30851037
[TBL] [Abstract][Full Text] [Related]
60. Contemporary use of P2Y
Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
